Nasdaq · CIK 0001671858
SPRY ARS Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing 7 d ago. Close $4.23 on Oct 9, 2026, +4% from the 52-week low and -68% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
19
with a Form 4 at this company
Price and insider trades, last year
SPRYOct 9, 2026 · close 4.23
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ARS Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 13Weak | Eric Karas Chief Commercial Officer sell | $240k 15,000 shares | -66% | +56% from low-9% from high | |
| 63Notable | Kathleen D. Scott Chief Financial Officer sell | $705k 50,000 shares | -87% | +41% from low-18% from high | |
| 60Notable | Brent L Saunders director sell | $1.7M 120,000 shares | -100% | +41% from low-18% from high | |
| 60Notable | Alexander A Fitzpatrick Chief Legal Officer sell | $1.5M 102,969 shares | -53% | +41% from low-18% from high | |
| 5Weak | Laura Shawver director sell | $615k 50,002 shares | -19% | +26% from low-27% from high | |
| 11Weak | Eric Karas Chief Commercial Officer sell | $140k 10,000 shares | -57% | +41% from low-18% from high | |
| 4Weak | Laura Shawver director sell | $560k 50,000 shares | -24% | +7% from low-38% from high | |
| 5Weak | Laura Shawver director sell | $616k 50,000 shares | -19% | +17% from low-30% from high | |
| 4Weak | Laura Shawver director sell | $555k 50,000 shares | -19% | +5% from low-37% from high | |
| 45Moderate | Richard E Lowenthal PRESIDENT AND CEO sell | $1.2M 100,000 shares | -7% | - | |
| 35Weak | Sarina Tanimoto CHIEF MEDICAL OFFICER sell | $1.2M 100,000 shares | -7% | - | |
| 38Weak | Brian Dorsey Chief Operating Officer sell | $494k 40,000 shares | -190% | - | |
| 60Notable | Justin Chakma Chief Business Officer sell | $1.8M 144,605 shares | -57% | - | |
| 45Moderate | Justin Chakma Chief Business Officer sell | $658k 50,000 shares | -27% | - | |
| 45Moderate | Richard E Lowenthal PRESIDENT AND CEO sell | $1.3M 100,000 shares | -8% | - | |
| 35Weak | Sarina Tanimoto CHIEF MEDICAL OFFICER sell | $1.3M 100,000 shares | -8% | - | |
| 60Notable | Justin Chakma Chief Business Officer sell | $2.0M 144,640 shares | -80% | - | |
| 26Weak | Eric Karas Chief Commercial Officer sell | $140k 10,000 shares | -106% | - | |
| 40Moderate | Laura Shawver director sell | $2.7M 200,000 shares | -65% | - | |
| 50Moderate | Justin Chakma Chief Business Officer sell | $1.2M 90,000 shares | -50% | - | |
| 65Notable | Justin Chakma Chief Business Officer sell | $1.4M 100,000 shares | -42% | - | |
| 35Weak | Sarina Tanimoto CHIEF MEDICAL OFFICER sell | $1.4M 100,000 shares | -7% | - | |
| 45Moderate | Richard E Lowenthal PRESIDENT AND CEO sell | $1.4M 100,000 shares | -7% | - | |
| 45Moderate | Richard E Lowenthal PRESIDENT AND CEO sell | $1.7M 100,000 shares | -7% | - | |
| 35Weak | Sarina Tanimoto CHIEF MEDICAL OFFICER sell | $1.7M 100,000 shares | -7% | - | |
| 57Moderate | James E Flynn owner sell | $10M 563,270 shares | -10% | - | |
| 45Moderate | Richard E Lowenthal PRESIDENT AND CEO sell | $1.5M 100,000 shares | -7% | - | |
| 35Weak | Sarina Tanimoto CHIEF MEDICAL OFFICER sell | $1.5M 100,000 shares | -7% | - | |
| 34Weak | Kathleen D. Scott Chief Financial Officer sell | $200k 12,500 shares | -72% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Donn Casale President and CEO | AGrant or award Stock Option (right to buy)derivative | +1,036,923 | $0.00 | $0 | 1,036,923 | 7 d ago |
| Sep 1, 2026 | Margaret Ekins Smith Chief Commercial Officer | AGrant or award Stock Option (right to buy)derivative | +1,001,738 | $0.00 | $0 | 1,001,738 | 40 d ago |
| Jun 25, 2025 | Laura Shawver director | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 27, 2025 |
| Jun 25, 2025 | Saqib Islam director | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 27, 2025 |
| Jun 25, 2025 | Brent L Saunders director | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 27, 2025 |
| Jun 25, 2025 | Ra Capital Management, L.p. director, owner | AGrant or award Stock Option (Right to Buy)derivativeindirect: See Footnotes | +30,000 | $0.00 | $0 | 30,000 | Jun 27, 2025 |
| Jun 25, 2025 | Michael Kelly director | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 27, 2025 |
| Jun 25, 2025 | Rajeev Dadoo director | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 27, 2025 |
| Jun 25, 2025 | Pratik Shah director | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 27, 2025 |
| Jun 25, 2025 | Phillip M Schneider director | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 27, 2025 |
| Jun 25, 2025 | Peter A. Thompson director | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 27, 2025 |
| Jun 18, 2025 | Eric Karas Chief Commercial Officer | MOption exercise Common Stock10b5-1 | +15,000 | $1.50 | $23k | 22,696 | Jun 20, 2025 |
| Jun 18, 2025 | Eric Karas Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -15,000 | $16.00 | $240k | 7,696 | Jun 20, 2025 |
| Jun 18, 2025 | Eric Karas Chief Commercial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 559,588 | Jun 20, 2025 |
| May 20, 2025 | Kathleen D. Scott Chief Financial Officer | MOption exercise Common Stock | +50,000 | $1.50 | $75k | 57,424 | May 22, 2025 |
| May 20, 2025 | Brent L Saunders director | MOption exercise Common Stock | +120,000 | $1.01 | $121k | 120,000 | May 22, 2025 |
| May 20, 2025 | Alexander A Fitzpatrick Chief Legal Officer | MOption exercise Common Stock | +100,000 | $5.58 | $558k | 192,582 | May 22, 2025 |
| May 20, 2025 | Kathleen D. Scott Chief Financial Officer | SOpen-market sale Common Stock | -50,000 | $14.10 | $705k | 7,424 | May 22, 2025 |
| May 20, 2025 | Alexander A Fitzpatrick Chief Legal Officer | SOpen-market sale Common Stock | -102,969 | $14.10 | $1.5M | 89,613 | May 22, 2025 |
| May 20, 2025 | Brent L Saunders director | SOpen-market sale Common Stock | -120,000 | $14.25 | $1.7M | 0 | May 22, 2025 |
| May 20, 2025 | Brent L Saunders director | MOption exercise Stock Option (Right to Buy)derivative | -120,000 | $0.00 | $0 | 470,950 | May 22, 2025 |
| May 20, 2025 | Alexander A Fitzpatrick Chief Legal Officer | MOption exercise Stock Option (Right to Buy)derivative | -100,000 | $0.00 | $0 | 200,000 | May 22, 2025 |
| May 20, 2025 | Kathleen D. Scott Chief Financial Officer | MOption exercise Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 752,330 | May 22, 2025 |
| Apr 7, 2025 | Laura Shawver director | MOption exercise Common Stock10b5-1 | +22,509 | $4.85 | $109k | 232,855 | Apr 8, 2025 |
| Apr 7, 2025 | Laura Shawver director | MOption exercise Common Stock10b5-1 | +27,493 | $4.85 | $133k | 260,348 | Apr 8, 2025 |
| Apr 7, 2025 | Laura Shawver director | SOpen-market sale Common Stock10b5-1 | -50,002 | $12.30 | $615k | 210,346 | Apr 8, 2025 |
| Apr 7, 2025 | Laura Shawver director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -22,509 | $0.00 | $0 | 51,555 | Apr 8, 2025 |
| Apr 7, 2025 | Laura Shawver director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -27,493 | $0.00 | $0 | 24,062 | Apr 8, 2025 |
| Mar 20, 2025 | Eric Karas Chief Commercial Officer | MOption exercise Common Stock10b5-1 | +10,000 | $1.50 | $15k | 17,696 | Mar 21, 2025 |
| Mar 20, 2025 | Eric Karas Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -10,000 | $14.00 | $140k | 7,696 | Mar 21, 2025 |
| Mar 20, 2025 | Eric Karas Chief Commercial Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 574,588 | Mar 21, 2025 |
| Mar 5, 2025 | Laura Shawver director | MOption exercise Common Stock10b5-1 | +400 | $4.85 | $1,940 | 210,746 | Mar 7, 2025 |
| Mar 5, 2025 | Laura Shawver director | SOpen-market sale Common Stock10b5-1 | -400 | $11.00 | $4,400 | 210,346 | Mar 7, 2025 |
| Mar 6, 2025 | Laura Shawver director | MOption exercise Common Stock10b5-1 | +49,600 | $4.85 | $241k | 259,946 | Mar 7, 2025 |
| Mar 6, 2025 | Laura Shawver director | SOpen-market sale Common Stock10b5-1 | -49,600 | $11.21 | $556k | 210,346 | Mar 7, 2025 |
| Mar 5, 2025 | Laura Shawver director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -400 | $0.00 | $0 | 123,664 | Mar 7, 2025 |
| Mar 6, 2025 | Laura Shawver director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -49,600 | $0.00 | $0 | 74,064 | Mar 7, 2025 |
| Feb 3, 2025 | Laura Shawver director | MOption exercise Common Stock10b5-1 | +9,064 | $3.15 | $29k | 219,410 | Feb 4, 2025 |
| Feb 3, 2025 | Laura Shawver director | MOption exercise Common Stock10b5-1 | +40,936 | $4.85 | $199k | 260,346 | Feb 4, 2025 |
| Feb 3, 2025 | Laura Shawver director | SOpen-market sale Common Stock10b5-1 | -50,000 | $12.31 | $616k | 210,346 | Feb 4, 2025 |
| Feb 3, 2025 | Laura Shawver director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,064 | $0.00 | $0 | 0 | Feb 4, 2025 |
| Feb 3, 2025 | Laura Shawver director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -40,936 | $0.00 | $0 | 124,064 | Feb 4, 2025 |
| Jan 6, 2025 | Laura Shawver director | MOption exercise Common Stock10b5-1 | +50,000 | $3.15 | $158k | 260,346 | Jan 7, 2025 |
| Jan 6, 2025 | Laura Shawver director | SOpen-market sale Common Stock10b5-1 | -50,000 | $11.10 | $555k | 210,346 | Jan 7, 2025 |
| Jan 6, 2025 | Laura Shawver director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -50,000 | $0.00 | $0 | 9,064 | Jan 7, 2025 |
| Jan 2, 2025 | Eric Karas Chief Commercial Officer | AGrant or award Stock option (right to buy)derivative | +152,300 | $0.00 | $0 | 152,300 | Jan 3, 2025 |
| Jan 2, 2025 | Kathleen D. Scott Chief Financial Officer | AGrant or award Stock option (right to buy)derivative | +176,700 | $0.00 | $0 | 176,700 | Jan 3, 2025 |
| Jan 2, 2025 | Justin Chakma Chief Business Officer | AGrant or award Stock option (right to buy)derivative | +274,100 | $0.00 | $0 | 274,100 | Jan 3, 2025 |
| Jan 2, 2025 | Brian Dorsey Chief Operating Officer | AGrant or award Stock option (right to buy)derivative | +261,900 | $0.00 | $0 | 261,900 | Jan 3, 2025 |
| Jan 2, 2025 | Alexander A Fitzpatrick Chief Legal Officer | AGrant or award Stock option (right to buy)derivative | +152,300 | $0.00 | $0 | 152,300 | Jan 3, 2025 |
| Jan 2, 2025 | Richard E Lowenthal PRESIDENT AND CEO | AGrant or award Stock option (right to buy)derivative | +767,600 | $0.00 | $0 | 767,600 | Jan 3, 2025 |
| Jan 2, 2025 | Sarina Tanimoto CHIEF MEDICAL OFFICER | AGrant or award Stock option (right to buy)derivative | +261,900 | $0.00 | $0 | 261,900 | Jan 3, 2025 |
| Jan 2, 2025 | Richard E Lowenthal PRESIDENT AND CEO | AGrant or award Stock Option (right to buy)derivativeindirect: By Spouse | +261,900 | $0.00 | $0 | 261,900 | Jan 3, 2025 |
| Jan 2, 2025 | Sarina Tanimoto CHIEF MEDICAL OFFICER | AGrant or award Stock Option (right to buy)derivativeindirect: By Spouse | +767,600 | $0.00 | $0 | 767,600 | Jan 3, 2025 |
| Dec 17, 2024 | Richard E Lowenthal PRESIDENT AND CEO | SOpen-market sale Common Stockindirect: By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 202010b5-1 | -50,000 | $11.67 | $584k | 1,297,447 | Dec 19, 2024 |
| Dec 17, 2024 | Sarina Tanimoto CHIEF MEDICAL OFFICER | SOpen-market sale Common Stockindirect: By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 202010b5-1 | -50,000 | $11.67 | $584k | 1,297,447 | Dec 19, 2024 |
| Dec 17, 2024 | Richard E Lowenthal PRESIDENT AND CEO | SOpen-market sale Common Stockindirect: By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/200610b5-1 | -50,000 | $11.67 | $584k | 1,098,499 | Dec 19, 2024 |
| Dec 17, 2024 | Sarina Tanimoto CHIEF MEDICAL OFFICER | SOpen-market sale Common Stockindirect: By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/200610b5-1 | -50,000 | $11.67 | $584k | 1,098,499 | Dec 19, 2024 |
| Dec 12, 2024 | Justin Chakma Chief Business Officer | MOption exercise Common Stock | +117,333 | $0.84 | $99k | 253,713 | Dec 13, 2024 |
| Dec 11, 2024 | Brian Dorsey Chief Operating Officer | MOption exercise Common Stock10b5-1 | +15,000 | $0.64 | $9,600 | 21,024 | Dec 13, 2024 |
| Dec 12, 2024 | Justin Chakma Chief Business Officer | SOpen-market sale Common Stock | -117,333 | $12.27 | $1.4M | 136,380 | Dec 13, 2024 |
| Dec 11, 2024 | Brian Dorsey Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -15,000 | $12.43 | $186k | 6,024 | Dec 13, 2024 |
| Dec 13, 2024 | Justin Chakma Chief Business Officer | MOption exercise Common Stock | +27,272 | $1.44 | $39k | 163,652 | Dec 13, 2024 |
| Dec 12, 2024 | Brian Dorsey Chief Operating Officer | MOption exercise Common Stock10b5-1 | +25,000 | $0.64 | $16k | 31,024 | Dec 13, 2024 |
| Dec 13, 2024 | Justin Chakma Chief Business Officer | SOpen-market sale Common Stock | -27,272 | $12.06 | $329k | 136,380 | Dec 13, 2024 |
| Dec 12, 2024 | Brian Dorsey Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -25,000 | $12.30 | $307k | 6,024 | Dec 13, 2024 |
| Dec 12, 2024 | Justin Chakma Chief Business Officer | MOption exercise Stock Option (Right to Buy)derivative | -117,333 | $0.00 | $0 | 119,047 | Dec 13, 2024 |
| Dec 11, 2024 | Brian Dorsey Chief Operating Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 46,828 | Dec 13, 2024 |
| Dec 12, 2024 | Brian Dorsey Chief Operating Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 21,828 | Dec 13, 2024 |
| Dec 13, 2024 | Justin Chakma Chief Business Officer | MOption exercise Stock Option (Right to Buy)derivative | -27,272 | $0.00 | $0 | 55,461 | Dec 13, 2024 |
| Dec 10, 2024 | Justin Chakma Chief Business Officer | MOption exercise Common Stock | +50,000 | $0.84 | $42k | 186,380 | Dec 12, 2024 |
| Dec 10, 2024 | Justin Chakma Chief Business Officer | SOpen-market sale Common Stock | -50,000 | $13.15 | $658k | 136,380 | Dec 12, 2024 |
| Dec 10, 2024 | Justin Chakma Chief Business Officer | MOption exercise Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | Dec 12, 2024 |
| Dec 10, 2024 | Richard E Lowenthal PRESIDENT AND CEO | SOpen-market sale Common Stockindirect: By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 202010b5-1 | -50,000 | $13.17 | $658k | 1,246,494 | Dec 11, 2024 |
| Dec 10, 2024 | Sarina Tanimoto CHIEF MEDICAL OFFICER | SOpen-market sale Common Stockindirect: By Richard Lowenthal Charitable Remainder UniTrust Dated January 7, 202010b5-1 | -50,000 | $13.17 | $658k | 1,246,494 | Dec 11, 2024 |
| Dec 10, 2024 | Richard E Lowenthal PRESIDENT AND CEO | SOpen-market sale Common Stockindirect: By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/200610b5-1 | -50,000 | $13.16 | $658k | 1,148,499 | Dec 11, 2024 |
| Dec 10, 2024 | Sarina Tanimoto CHIEF MEDICAL OFFICER | SOpen-market sale Common Stockindirect: By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/200610b5-1 | -50,000 | $13.16 | $658k | 1,148,499 | Dec 11, 2024 |
| Dec 6, 2024 | Richard E Lowenthal PRESIDENT AND CEO | MOption exercise Common Stock | +11,876 | $8.42 | $100k | 4,327,189 | Dec 9, 2024 |
| Dec 6, 2024 | Sarina Tanimoto CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +13,789 | $1.44 | $20k | 3,421,636 | Dec 9, 2024 |
| Dec 6, 2024 | Richard E Lowenthal PRESIDENT AND CEO | MOption exercise Common Stockindirect: By Spouse | +13,789 | $1.44 | $20k | 3,421,636 | Dec 9, 2024 |
| Dec 6, 2024 | Sarina Tanimoto CHIEF MEDICAL OFFICER | MOption exercise Common Stock | +11,876 | $8.42 | $100k | 3,433,512 | Dec 9, 2024 |
| Dec 6, 2024 | Richard E Lowenthal PRESIDENT AND CEO | MOption exercise Common Stockindirect: By Spouse | +11,876 | $8.42 | $100k | 3,433,512 | Dec 9, 2024 |
| Dec 6, 2024 | Sarina Tanimoto CHIEF MEDICAL OFFICER | MOption exercise Common Stockindirect: By Spouse | +11,876 | $8.42 | $100k | 4,327,189 | Dec 9, 2024 |
| Dec 6, 2024 | Richard E Lowenthal PRESIDENT AND CEO | MOption exercise Stock Option (right to buy)derivative | -11,876 | $0.00 | $0 | 1,088,124 | Dec 9, 2024 |
| Dec 6, 2024 | Sarina Tanimoto CHIEF MEDICAL OFFICER | MOption exercise Stock Option (right to buy)derivative | -13,789 | $0.00 | $0 | 20,684 | Dec 9, 2024 |
| Dec 6, 2024 | Richard E Lowenthal PRESIDENT AND CEO | MOption exercise Stock Option (right to buy)derivativeindirect: By Spouse | -13,789 | $0.00 | $0 | 20,684 | Dec 9, 2024 |
| Dec 6, 2024 | Sarina Tanimoto CHIEF MEDICAL OFFICER | MOption exercise Stock Option (right to buy)derivative | -11,876 | $0.00 | $0 | 338,124 | Dec 9, 2024 |
| Dec 6, 2024 | Richard E Lowenthal PRESIDENT AND CEO | MOption exercise Stock Option (right to buy)derivativeindirect: By Spouse | -11,876 | $0.00 | $0 | 338,124 | Dec 9, 2024 |
| Dec 6, 2024 | Sarina Tanimoto CHIEF MEDICAL OFFICER | MOption exercise Stock Option (right to buy)derivativeindirect: By Spouse | -11,876 | $0.00 | $0 | 1,088,124 | Dec 9, 2024 |
| Dec 4, 2024 | Justin Chakma Chief Business Officer | MOption exercise Common Stock | +45,000 | $0.84 | $38k | 181,380 | Dec 6, 2024 |
| Dec 4, 2024 | Justin Chakma Chief Business Officer | SOpen-market sale Common Stock | -45,000 | $13.95 | $628k | 136,380 | Dec 6, 2024 |
| Dec 5, 2024 | Justin Chakma Chief Business Officer | MOption exercise Common Stock | +49,640 | $0.84 | $42k | 186,020 | Dec 6, 2024 |
| Dec 5, 2024 | Justin Chakma Chief Business Officer | SOpen-market sale Common Stock | -49,640 | $14.13 | $702k | 136,380 | Dec 6, 2024 |
| Dec 6, 2024 | Justin Chakma Chief Business Officer | MOption exercise Common Stock | +50,000 | $0.84 | $42k | 186,380 | Dec 6, 2024 |
| Dec 6, 2024 | Justin Chakma Chief Business Officer | SOpen-market sale Common Stock | -50,000 | $14.23 | $712k | 136,380 | Dec 6, 2024 |
| Dec 4, 2024 | Justin Chakma Chief Business Officer | MOption exercise Stock Option (Right to Buy)derivative | -45,000 | $0.00 | $0 | 149,640 | Dec 6, 2024 |
| Dec 5, 2024 | Justin Chakma Chief Business Officer | MOption exercise Stock Option (Right to Buy)derivative | -49,640 | $0.00 | $0 | 100,000 | Dec 6, 2024 |
| Dec 6, 2024 | Justin Chakma Chief Business Officer | MOption exercise Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 50,000 | Dec 6, 2024 |
| Dec 2, 2024 | Laura Shawver director | MOption exercise Common Stock10b5-1 | +67,616 | $1.27 | $86k | 277,962 | Dec 4, 2024 |
| Dec 2, 2024 | Eric Karas Chief Commercial Officer | MOption exercise Common Stock10b5-1 | +3,717 | $1.50 | $5,576 | 9,410 | Dec 4, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Donn CasalePresident and CEO
- Justin ChakmaChief Business Officer
- Rajeev Dadoodirector
- Brian DorseyChief Operating Officer
- Alexander A FitzpatrickChief Legal Officer
- James E Flynnowner, director, other
- Saqib Islamceo, officer, director
- Eric KarasChief Commercial Officer
- Michael Kellydirector
- Richard E LowenthalPRESIDENT AND CEO
- Ra Capital Management, L.p.owner, director
- Brent L Saundersceo, chair, officer, director, other
- Phillip M Schneiderdirector
- Kathleen D. ScottChief Financial Officer
- Pratik Shahceo, president, chair, officer, director
- Laura Shawverdirector
- Margaret Ekins SmithChief Commercial Officer
- Sarina TanimotoCHIEF MEDICAL OFFICER
- Peter A. Thompsondirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.